Compugen Ltd (CGEN) stock

CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026Score 12/30

$2.10−0.02 (-0.94%)

Close on Nov 13, 2026Market cap $198.56MP/E 5.5Yield –

Compugen statistics

92 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Jun 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $198.56M; $272.32M
Enterprise Value: $148.60M; $146.23M
PE Ratio: 5.53; 25.11
PS Ratio: 2.73; 3.66
PB Ratio: 2.24; 2.00
P/TBV Ratio: 2.24; 2.22
P/FCF Ratio: 6.34; 17.86
P/OCF Ratio: 6.28; 12.99

Enterprise valuationIndustry

EV / Sales: 2.04; 2.57
EV / EBITDA: 4.74; 16.50
EV / EBIT: 4.74; 19.31
EV / FCF: 4.74; 22.27

Share statisticsIndustry

Shares Outstanding: 95M; 58M
Shares Change (YoY): 4.79%; 10.8%
Float: 94M; 49M
Shares Held by Insiders: 0.43%; 11.7%

Short sellingIndustry

Short Interest: 3M; –
Short Interest Change: 0.52%; -0.80%
Short % of Float: 2.69%; 9.01%
Short % of Shares Outstanding: 2.67%; 6.30%
Days to Cover: 9.70; 5.15

Stock price statisticsIndustry

52-Week High: $3.23; –
52-Week Low: $1.43; –
20-Day Moving Average: $2.02; –
50-Day Moving Average: $2.20; –
200-Day Moving Average: $2.29; –
Average True Range (14): $0.10; –
Price Change (1 Week): 7.14%; -1.15%
Price Change (1 Month): 0.96%; -4.87%
Price Change (3 Months): -10.6%; -21.0%
Price Change (6 Months): -23.6%; -20.6%
Price Change (YTD): 37.3%; -23.6%
Price Change (1 Year): 25.0%; -22.4%
Price Change (3 Years): 261.4%; -29.5%
Price Change (5 Years): -64.2%; -77.9%
Price Change (10 Years): -68.9%; -65.4%
Average Volume (10 Days): 216,741; –
Average Volume (20 Days): 244,200; –
Average Volume (90 Days): 241,124; –
Relative Volume: 0.86; 0.70
Relative Strength Index (14): 51.2; 43.4
Volatility (1 Year): 64.4%; 80.1%
Beta (5 Years): 1.60; 1.07

MarginsIndustry

Gross Margin: 87.3%; 53.1%
Operating Margin: 43.1%; -38.7%
Pretax Margin: 48.6%; -11.6%
Profit Margin: 48.6%; -31.6%
EBITDA Margin: 43.1%; -27.7%
FCF Margin: 43.1%; -9.56%

Returns on capitalIndustry

Return on Equity (ROE): 50.9%; -49.9%
Return on Assets (ROA): 28.9%; -40.6%
Return on Invested Capital (ROIC): 116.5%; -32.9%
Return on Capital Employed (ROCE): 27.1%; -37.9%

Financial positionIndustry

Current Ratio: 5.72; 3.30
Quick Ratio: 2.24; 2.39

GrowthIndustry

Revenue Growth (YoY): 161.1%; 6.82%
FCF Growth (YoY): -36.7%; 6.85%
Revenue Growth (3Y CAGR): 113.3%; 2.25%
Revenue Growth (5Y CAGR): 105.2%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.59; 0.40
Revenue Per Employee: $36.38M; $429.29K
Profits Per Employee: $17.67M; -$689.41K
Employee Count: 2; 74
WACC: 13.1%; 10.2%

Income statement (TTM)Industry

Revenue: $72.76M; $66.37M
Gross Profit: $63.51M; $120.78M
Operating Income: $31.33M; -$21.37M
Pretax Income: $35.40M; -$12.95M
Net Income: $35.34M; -$22.35M
EBITDA: $31.33M; -$17.21M
EPS (Diluted): $0.38; -$0.76

Balance sheetIndustry

Cash & Short-Term Investments: $49.96M; $68.68M
Net Cash (Debt): $49.96M; $17.76M
Net Cash Per Share: $0.53; $0.80
Equity (Book Value): $88.73M; $53.89M
Book Value Per Share: $0.94; $1.50
Tangible Book Value: $88.73M; $27.13M
Working Capital: $106.78M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: $31.63M; -$12.38M
Capital Expenditures: -$306.00K; -$1.00M
Free Cash Flow: $31.33M; -$18.21M
FCF Per Share: $0.33; -$0.42

Dividends and yieldsIndustry

Earnings Yield: 17.8%; -21.8%
FCF Yield: 15.8%; -9.44%
Buyback Yield: -5.31%; -0.76%
Shareholder Yield: -5.31%; 0.00%

Taxes and interestIndustry

Income Tax: $54.00K; $73.00K
Effective Tax Rate: 0.15%; 20.9%

Scores and fair valueIndustry

Graham Number: $2.83; $19.34
Graham Upside: 34.9%; -46.6%
Altman Z-Score: -0.14; 0.23
Piotroski F-Score: 7; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	CGEN	S&P 500	Difference	CGEN per year	S&P 500 per year
1 month	+6.1%	-3.0%	+9.1 pts
3 months	-12.9%	-2.8%	−10.1 pts
Year to date	+37.3%	+11.5%	+25.8 pts
1 year	+27.3%	+13.5%	+13.8 pts
3 years	+296.2%	+77.7%	+218.5 pts	+58.2%	+21.1%
5 years	-64.2%	+72.6%	−136.8 pts	-18.6%	+11.5%
10 years	-68.4%	+308.2%	−376.6 pts	-10.9%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

3M CGEN shares were sold short on Oct 30, 2026, up 0.5% from the previous report, or 2.69% of the shares available to trade. At recent volumes it would take 9.7 days to buy them back. Over the last 20 sessions, 43.8% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	2,528,041	+0.5%	260,671	9.7
Oct 15, 2026	2,515,022	+6.8%	198,701	12.7
Sep 30, 2026	2,354,274	-0.5%	146,212	16.1
Sep 15, 2026	2,366,980	+0.8%	197,031	12.0
Aug 31, 2026	2,349,292	-22.5%	384,481	6.1
Aug 14, 2026	3,032,032	+7.7%	302,937	10.0
Jul 31, 2026	2,814,877	-7.0%	216,201	13.0
Jul 15, 2026	3,027,148	+8.2%	271,054	11.2
Jun 30, 2026	2,797,911	-2.5%	280,318	10.0
Jun 15, 2026	2,869,956	+17.2%	502,592	5.7
May 29, 2026	2,449,496	+44.8%	622,672	3.9
May 15, 2026	1,691,130	+18.9%	447,622	3.8